BE2015C050I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C050I2
BE2015C050I2 BE2015C050C BE2015C050C BE2015C050I2 BE 2015C050 I2 BE2015C050 I2 BE 2015C050I2 BE 2015C050 C BE2015C050 C BE 2015C050C BE 2015C050 C BE2015C050 C BE 2015C050C BE 2015C050 I2 BE2015C050 I2 BE 2015C050I2
Authority
BE
Belgium
Application number
BE2015C050C
Other languages
French (fr)
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36660051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C050(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of BE2015C050I2 publication Critical patent/BE2015C050I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2015C050C 2003-12-18 2015-09-17 BE2015C050I2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030093342 2003-12-18
KR1020040058809A KR100854211B1 (ko) 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물

Publications (1)

Publication Number Publication Date
BE2015C050I2 true BE2015C050I2 (enExample) 2024-08-08

Family

ID=36660051

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C050C BE2015C050I2 (enExample) 2003-12-18 2015-09-17

Country Status (25)

Country Link
US (9) US7816379B2 (enExample)
EP (2) EP1699784B1 (enExample)
JP (1) JP4739229B2 (enExample)
KR (1) KR100854211B1 (enExample)
CN (4) CN1894242B (enExample)
AT (1) ATE514686T1 (enExample)
AU (2) AU2004299413C1 (enExample)
BE (1) BE2015C050I2 (enExample)
BR (1) BRPI0417800B8 (enExample)
CA (1) CA2549062C (enExample)
CY (2) CY1112445T1 (enExample)
DK (1) DK1699784T3 (enExample)
ES (1) ES2391820T3 (enExample)
FR (1) FR15C0062I2 (enExample)
HU (1) HUS1500046I1 (enExample)
LT (1) LTC1699784I2 (enExample)
LU (1) LU92834I2 (enExample)
MX (2) MXPA06006955A (enExample)
NL (1) NL300759I2 (enExample)
NZ (2) NZ547928A (enExample)
PL (1) PL1699784T3 (enExample)
PT (1) PT1699784E (enExample)
RU (2) RU2414469C3 (enExample)
SI (1) SI1699784T1 (enExample)
WO (1) WO2005058886A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
AU2004267007C1 (en) 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500319A (ja) * 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 細菌感染症の治療のためのｍａｏ阻害剤としての３−（４−（２−ジヒドロイソオキサゾール−３−イルピリジン−５−イル）フェニル−５−トリアゾール−１−イルメチルオキサゾリジン−２−オン誘導体
WO2006038100A1 (en) * 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
CN100406455C (zh) * 2006-02-20 2008-07-30 中国科学院上海药物研究所 含三氮唑基的噁唑烷酮类化合物及其制备方法和用途
MX2009004764A (es) * 2006-11-10 2009-05-21 Actelion Pharmaceuticals Ltd Derivados de 5-hidroximetil-oxazolidin-2-ona.
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
BRPI0911991B8 (pt) * 2008-05-09 2021-05-25 Actelion Pharmaceuticals Ltd derivados de 5-hidroximetil-oxazolidin-2-ona para o tratamento de doenças intestinais bacterianas
US20100069441A1 (en) 2008-09-02 2010-03-18 Mikhail Fedorovich Gordeev Antimicrobial indoline compounds for treatment of bacterial infections
MX366793B (es) * 2008-10-10 2019-07-24 Merck Sharp & Dohme Corp Star Metodos para preparar oxazolidinonas y composiciones que las contienen.
JP6063123B2 (ja) 2008-11-15 2017-01-18 メリンタ セラピューティクス、インク 抗菌性組成物
CN102224151A (zh) 2008-11-20 2011-10-19 万能药生物有限公司 新的抗微生物剂
WO2010061908A1 (ja) 2008-11-28 2010-06-03 中外製薬株式会社 １－（２ｈ）－イソキノロン誘導体
KR101739923B1 (ko) 2009-02-03 2017-05-25 머크 샤프 앤드 돔 코포레이션 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
CN101798302B (zh) 2009-02-06 2014-11-05 上海盟科药业有限公司 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺
KR20110136850A (ko) 2009-03-13 2011-12-21 썬 케미칼 비.브이. 에너지-경화성 조성물에 유용한 사이클릭 카바메이트 화합물
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
JP5696142B2 (ja) 2009-06-26 2015-04-08 パナセア バイオテック リミテッド 新規アザビシクロヘキサン類
WO2011046905A2 (en) * 2009-10-13 2011-04-21 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions
IT1397023B1 (it) 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
ES2368236B1 (es) * 2009-12-23 2012-09-26 Merck Sharp & Dohme Corp. Agentes antibacterianos.
CN102276595A (zh) * 2010-04-16 2011-12-14 山东轩竹医药科技有限公司 含有五元杂环的噁唑烷酮抗菌素
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
WO2012033952A1 (en) 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. 3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infections
US9409896B2 (en) 2010-11-01 2016-08-09 Melinta Therapeutics, Inc. Sustained release pharmaceutical compositions comprising an antibacterial agent
ES2836809T3 (es) 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
EP2671877A4 (en) * 2011-01-31 2015-07-01 Univ Nagasaki PROCESS FOR PREPARING OPTICALLY ACTIVE COMPOUNDS OR SALTS OF THE SAME
KR101653570B1 (ko) * 2011-03-30 2016-09-02 주식회사 레고켐 바이오사이언스 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
HK1199250A1 (en) 2011-09-29 2015-06-26 山东轩竹医药科技有限公司 Biaryl heterocycle substituted oxazolidinon antibacterial drug
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
CN103896963B (zh) * 2012-12-26 2017-06-09 中国科学院上海药物研究所 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
KR101480982B1 (ko) * 2013-03-20 2015-02-03 (주)셀인바이오 골형성 유도 화합물 및 이의 응용
CN104650142B (zh) * 2013-11-25 2018-06-22 山东新时代药业有限公司 一种福沙匹坦二甲葡胺的制备方法
KR102428252B1 (ko) 2014-02-21 2022-08-02 상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드 치료적 투여용 수용성 o-카보닐 포스포르아미데이트 전구약물
US10189870B2 (en) 2014-04-18 2019-01-29 Hangzhou Pushai Pharmaeutical Technology Co., Ltd. Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN105566392B (zh) * 2014-10-15 2018-12-21 正大天晴药业集团股份有限公司 一种细菌蛋白质合成抑制剂的制备方法
CN105503955B (zh) * 2014-10-15 2018-11-20 正大天晴药业集团股份有限公司 一种抗革兰氏阳性菌的化合物的制备方法
CN105418678B (zh) * 2014-09-17 2018-11-20 正大天晴药业集团股份有限公司 一种磷酸特地唑胺的制备方法
CN106928214A (zh) * 2014-09-17 2017-07-07 博瑞生物医药（苏州）股份有限公司 一种噁唑烷酮类化合物及其中间体的制备方法
WO2016041505A1 (zh) * 2014-09-17 2016-03-24 正大天晴药业集团股份有限公司 一种磷酸特地唑胺、其中间体以及它们的制备方法
CN105837633B (zh) * 2015-01-12 2018-11-20 正大天晴药业集团股份有限公司 一种抗菌化合物的制备方法
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088103A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited A process for the preparation of tedizolid phosphate
CN104530128B (zh) * 2014-12-30 2016-08-24 石药集团中诺药业（石家庄）有限公司 一种磷酸特地唑胺二钠盐及其制备方法
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105859780A (zh) * 2015-01-21 2016-08-17 山东康美乐医药科技有限公司 磷酸特地唑胺的制备方法
CN104610359B (zh) * 2015-01-26 2017-07-14 成都新恒创药业有限公司 一种制备磷酸特地唑胺的关键中间体及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN110078764B (zh) * 2015-04-10 2021-10-26 博瑞生物医药（苏州）股份有限公司 一种噁唑烷酮类化合物的制备方法
CN106279281B (zh) * 2015-05-15 2018-08-03 重庆圣华曦药业股份有限公司 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN106632298B (zh) * 2015-11-03 2021-06-01 上海科胜药物研发有限公司 一种泰地唑胺的制备方法及其中间体
KR101855334B1 (ko) 2015-12-11 2018-06-08 에스티팜 주식회사 옥사졸리디논 유도체의 중간체 제조방법
CN105496976A (zh) * 2015-12-18 2016-04-20 北京万全德众医药生物技术有限公司 一种磷酸特地唑胺片及其制备方法
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
CN106083994B (zh) * 2016-04-18 2019-12-06 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
WO2017181948A1 (zh) * 2016-04-22 2017-10-26 深圳市塔吉瑞生物医药有限公司 取代的恶唑烷酮化合物及其应用
CN107400126A (zh) * 2016-05-19 2017-11-28 陕西合成药业股份有限公司 新型噁唑烷酮类化合物及其制备方法和在医学上的应用
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN106632240A (zh) * 2016-11-25 2017-05-10 山东轩德医药科技有限公司 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid
CN107226825B (zh) * 2017-06-14 2019-08-02 浙江海正药业股份有限公司 磷酸泰地唑胺铵盐及其晶型、制备方法和医药用途
US11452719B2 (en) 2017-12-13 2022-09-27 Merck Sharp & Dohme Llc Pharmaceutical compositions of tedizolid phosphate
CN110804038B (zh) * 2018-08-06 2021-03-05 上海博志研新药物技术有限公司 磷酸特地唑胺及其中间体的制备方法
WO2020147504A1 (en) * 2019-01-18 2020-07-23 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
CN117567455A (zh) * 2019-12-11 2024-02-20 华创合成制药股份有限公司 一种新型噁唑烷酮类化合物及其合成方法和应用
CN111116551B (zh) * 2020-01-03 2022-05-20 中国医科大学 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物
MX2022016063A (es) 2020-06-18 2023-04-11 Akagera Medicines Inc Compuestos de oxazolidinona, composiciones de liposomas que comprenden compuestos de oxazolidinona y metodos de uso de los mismos.
CN115968290A (zh) * 2020-06-18 2023-04-14 阿卡格拉医药公司 噁唑烷酮类化合物、包含噁唑烷酮类化合物的脂质体组合物、及其使用方法
CN114315897B (zh) * 2020-09-30 2024-05-17 北京澳合药物研究院有限公司 一种磷酸特地唑胺新晶体及其制备方法
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN112500433A (zh) * 2020-12-23 2021-03-16 桂林南药股份有限公司 一种磷酸特地唑胺的制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂
WO2023122759A2 (en) * 2021-12-22 2023-06-29 Akagera Medicines, Inc. Oxazolidinone liposome compositions
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) * 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
HUT74099A (en) * 1992-12-08 1996-11-28 Upjohn Co Tropone-substituted phenyloxazolidinone antibacterial agents and pharmaceutical compositions containing the same
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
FI980452A7 (fi) * 1995-09-01 1998-02-27 Upjohn Co Fenyylioksatsolidinoneja, jotka ovat liittyneet C-C-sidoksella 4-8-jäs enisiin heterosyklisiin renkaisiin
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
WO1999002525A1 (en) 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
ES2207010T3 (es) * 1997-11-12 2004-05-16 PHARMACIA & UPJOHN COMPANY Derivados de oxazolidinona y composiciones farmaceuticas.
JP2002515450A (ja) * 1998-05-18 2002-05-28 ファルマシア・アンド・アップジョン・カンパニー アルギニン誘導体を用いることによるオキサゾリジノン抗細菌剤活性の向上
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
KR100731469B1 (ko) * 2000-06-05 2007-06-21 동아제약주식회사 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR100713170B1 (ko) * 2001-03-07 2007-05-02 동아제약주식회사 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법
MXPA02012045A (es) * 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Nuevos derivados de oxazolidinona y proceso para su preparacion.
US20020115669A1 (en) 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
WO2002081470A1 (en) 2001-04-07 2002-10-17 Astrazeneca Ab Oxazolidinones containing a sulfonimid group as antibiotics
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
IL160739A0 (en) 2001-09-11 2004-08-31 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
WO2003035648A1 (en) 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
KR20040086465A (ko) 2002-02-28 2004-10-08 아스트라제네카 아베 화합물
NZ540147A (en) 2002-11-28 2008-03-28 Astrazeneca Ab Oxazolidinone and/or isoxazoline derivatives as antibacterial agents
CA2507628A1 (en) 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
AU2004256085B2 (en) * 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
MXPA06000228A (es) * 2003-07-02 2006-06-27 Merck & Co Inc Antibioticos de oxazolidinona sustituidos con un grupo ciclopropilo y derivados de los mismos.
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2005051933A1 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
US7129259B2 (en) * 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20080064689A1 (en) 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
EP1753755A1 (en) 2004-05-25 2007-02-21 AstraZeneca AB 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
JP2008500319A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 細菌感染症の治療のためのｍａｏ阻害剤としての３−（４−（２−ジヒドロイソオキサゾール−３−イルピリジン−５−イル）フェニル−５−トリアゾール−１−イルメチルオキサゾリジン−２−オン誘導体
BRPI0511526A (pt) 2004-05-25 2007-12-26 Astrazeneca Ab composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
WO2006038100A1 (en) 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20090018123A1 (en) 2005-06-20 2009-01-15 Milind D Sindkhedkar Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
CA2695616C (en) 2007-08-06 2015-11-24 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
MX366793B (es) 2008-10-10 2019-07-24 Merck Sharp & Dohme Corp Star Metodos para preparar oxazolidinonas y composiciones que las contienen.
KR101739923B1 (ko) 2009-02-03 2017-05-25 머크 샤프 앤드 돔 코포레이션 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
RU2006125761A (ru) 2008-01-27
RU2559620C2 (ru) 2015-08-10
EP1699784B1 (en) 2011-06-29
CA2549062C (en) 2011-07-05
CN101982468A (zh) 2011-03-02
US20200078345A1 (en) 2020-03-12
EP2305657A3 (en) 2011-04-27
ES2391820T3 (es) 2012-11-30
EP1699784A4 (en) 2008-09-03
FR15C0062I1 (fr) 2015-10-30
NL300759I1 (enExample) 2015-12-22
KR100854211B1 (ko) 2008-08-26
AU2004299413A1 (en) 2005-06-30
CN101982468B (zh) 2012-02-08
EP2305657B1 (en) 2012-08-22
DK1699784T3 (da) 2011-10-10
ATE514686T1 (de) 2011-07-15
CN1894242B (zh) 2012-07-04
CY2015036I2 (el) 2016-06-22
US7816379B2 (en) 2010-10-19
PT1699784E (pt) 2011-10-06
CN102516238A (zh) 2012-06-27
RU2414469C3 (ru) 2017-06-14
SI1699784T1 (sl) 2011-11-30
LU92834I2 (fr) 2015-11-17
US20210121449A1 (en) 2021-04-29
CN102702184B (zh) 2016-06-08
LTC1699784I2 (lt) 2017-09-11
WO2005058886A1 (en) 2005-06-30
CN1894242A (zh) 2007-01-10
US20090192197A1 (en) 2009-07-30
AU2009200606B2 (en) 2011-01-06
EP1699784A1 (en) 2006-09-13
MX339597B (es) 2016-06-01
CN102702184A (zh) 2012-10-03
HK1153738A1 (en) 2012-04-05
CY2015036I1 (el) 2016-06-22
BRPI0417800B8 (pt) 2021-05-25
JP4739229B2 (ja) 2011-08-03
PL1699784T3 (pl) 2011-11-30
HK1155747A1 (en) 2012-05-25
AU2009200606A1 (en) 2009-03-05
KR20050061271A (ko) 2005-06-22
EP2305657A2 (en) 2011-04-06
US20170049763A1 (en) 2017-02-23
CN102516238B (zh) 2016-08-03
HUS1500046I1 (hu) 2017-05-29
AU2004299413B2 (en) 2008-11-20
RU2010149618A (ru) 2012-06-27
US8420676B2 (en) 2013-04-16
US9163043B2 (en) 2015-10-20
US20180344716A1 (en) 2018-12-06
JP2007514737A (ja) 2007-06-07
MXPA06006955A (es) 2006-12-19
FR15C0062I2 (fr) 2016-08-26
CA2549062A1 (en) 2005-06-30
US20140350059A1 (en) 2014-11-27
BRPI0417800B1 (pt) 2019-10-08
US20170333414A1 (en) 2017-11-23
CY1112445T1 (el) 2015-12-09
AU2004299413C1 (en) 2009-07-02
NL300759I2 (enExample) 2015-12-22
RU2414469C2 (ru) 2011-03-20
NZ575842A (en) 2010-10-29
US20130281492A1 (en) 2013-10-24
BRPI0417800A (pt) 2007-04-10
US20070155798A1 (en) 2007-07-05
NZ547928A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
BE2015C050I2 (enExample)
FR14C0056I1 (enExample)
BE2013C075I2 (enExample)
BE2013C070I2 (enExample)
BE2013C067I2 (enExample)
BE2013C038I2 (enExample)
BE2013C036I2 (enExample)
JP2004000655A5 (enExample)
JP2004046115A5 (enExample)
BE2011C030I2 (enExample)
JP2004086137A5 (enExample)
DE602004028019D1 (enExample)
JP2003317580A5 (enExample)
JP2004005637A5 (enExample)
BE2013C034I2 (enExample)
JP2004150433A5 (enExample)
BE2012C053I2 (enExample)
JP2004160999A5 (enExample)
JP2003291303A5 (enExample)
JP2004220513A5 (enExample)
JP2004147287A5 (enExample)
JP2004212870A5 (enExample)
AU2003210772A1 (enExample)
AU2002341905A1 (enExample)
JP2004130088A5 (enExample)